medigraphic.com

2017, Number 2

Next >>

Rev Cuba Endoc 2017; 28 (2)

What will be the best strategy for screening of impaired glucose metabolism in the primary health care?

Arnold Domínguez Y, Cabrera-Rode E

Language: Spanish
References: 27
Page: 1-7
PDF size: 76.92 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Fernández JA, Díaz J. Algunas consideraciones teóricas sobre la pesquisa activa. Rev Cubana Med Gen Integr [serie en Internet]. 2009 Dic [citado 5 de junio de 2017];25(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 21252009000400011&lng=es&nrm=iso&tlng=es

  2. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(sup 1):S1-S135.

  3. Asociación Latinoamericana de Diabetes. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia, edición 2013. Revista ALAD. 2013:1-148.

  4. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130-5.

  5. Díaz O, Cabrera Rode E, Orlandi González N, Araña Rosaínz MJ, Díaz Horta O. Aspectos epidemiológicos de la prediabetes, diagnóstico y clasificación. Rev Cubana Endocrinol. 2011;22 (1):3-10.

  6. Arnold M, Arnold Y, Alfonso Y, Villar C, González TM. Pesquisaje y prevención de la diabetes mellitus tipo 2 en población de riesgo. Rev Cubana Hig Epidemiol [serie en Internet]. 2012 Dic [citado 25 de mayo de 2017];50(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 30032012000300012&lng=es&nrm=iso&tlng=es

  7. Colectivo de autores. Manual para el diagnóstico y tratamiento del paciente diabético a nivel primario de salud. OPS/OMS-Cuba. La Habana: OPS/OMS; 2011.

  8. DeFronzo RA, Mandarino L, Ferrannini E. Metabolic and molecular pathogenesis of type 2 diabetes mellitus. En: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. New York: John Wiley & Sons; 2004. p. 389-438.

  9. Davidson M, Schriger D, Peters A, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281:1203-10.

  10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care. 2003;26:3160-7.

  11. DECODE-study group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of european epidemiological data. BMJ. 1998;317:371-5.

  12. Aekplakorn W, Tantayotai V, Numsangkul S, Sripho W, Tatsato N, Burapasiriwat T, et al. Detecting Prediabetes and Diabetes: Agreement between Fasting Plasma Glucose and Oral Glucose Tolerance Test in Thai Adults. Journal of Diabetes Research. 2015;(2015).Article ID 396505.doi:10.1155/2015/.

  13. Pieri M, Pignalosa S, Zenobi R, Callá C, Martino FG, Menichella G, et al. Glycated hemoglobin according to gender: possible reference values. Rev Ital Med Lab. 2016;53:1053-6.

  14. Chilelli NC, Cosma C, Ragazzi E, Burlina S, Zaninotto M, Plebani M, et al. Screening with HbA1c identifies only one in two individuals with diagnosis of prediabetes at oral glucose tolerance test: findings in a real-world Caucasian population. Acta Diabetol. 2016;51(5):875-82.

  15. Guo F, Moellering DR, Garvey WT. Use of HbA1c for Diagnoses of Diabetes and Prediabetes: Comparison with Diagnoses Based on Fasting and 2-Hr Glucose Values and Effects of Gender, Race, and Age. Metabolic Syndrome and Related Disorders. 2014;12(5):258-68.

  16. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-105.

  17. The DECODE Study Group. Age-and sex-specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61-9.

  18. Karvonen M, Tuomilehto J, Libman I, LaPorte R. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulindependent) diabetes mellitus: World Health Organization DiaMond Project Group. Diabetología. 1993;36:883-92.

  19. Helgason T, Danielsen R, Thorsson AV. Incidence and prevalence of type 1 (insulin-dependent) diabetes mellitus in Icelandic children, 1970-1989. Diabetología. 1992;35:880-3.

  20. Tuomilehto J, Lindström J, Hellmich M, Lehmacher W, Westermeiere T, Evers T, et al. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score. Diab Res Clin Pract. 2010;87(2):267-74.

  21. Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011;92(1):46-52.

  22. Cuba. Minsap. Temas de Estadísticas de Salud. Dirección Nacional de Estadísticas y Registros Médicos. La Habana: Minsap; 2002.

  23. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al. Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 DM in the diabetes prevention program. Diabetes Care. 2003;26:36-47.

  24. Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26:725-31.

  25. Schwarz PEH, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res. 2009;41(2):86-97.

  26. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ [serie en Internet]. 2011 [citado 6 de abril de 2017];343:d7163. Disponible en: http://www.bmj.com/content/bmj/343/bmj.d7163.full.pdf

  27. Salinero MÁ, de Burgos-Lunar C, Mostaza Prieto J, Salinero MA, de Burgos C, Mostaza J, et al. Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol. BMJ Open. 2015;5(7):e007195. doi:10.1136/bmjopen-2014-007195.




2020     |     www.medigraphic.com